Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone215-862-9720
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
Next Earnings Date4/26/2019 (Estimated)
OptionableNot Optionable
Protalex (OTCMKTS:PRTX) Frequently Asked Questions
What is Protalex's stock symbol?
Protalex trades on the OTCMKTS under the ticker symbol "PRTX."
How were Protalex's earnings last quarter?
Protalex Inc. (OTCMKTS:PRTX) released its quarterly earnings data on Friday, April, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. View Protalex's Earnings History.
When is Protalex's next earnings date?
Has Protalex been receiving favorable news coverage?
News coverage about PRTX stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Protalex earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Protalex's key competitors?
What other stocks do shareholders of Protalex own?
Who are Protalex's key executives?
Protalex's management team includes the folowing people:
- Mr. Arnold P. Kling Esq., Pres & Director (Age 61)
- Dr. William E. Gannon Jr., Chief Medical Officer & Member of Scientific Advisory Board
- Dr. John Bruce Lundy McClain M.D., Medical Director & Member of Scientific Advisory Board
- Dr. Michelle Catalina Ph.D., Director of Preclinical Studies & Member of Scientific Advisory Board
How do I buy shares of Protalex?
Shares of PRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalex's stock price today?
One share of PRTX stock can currently be purchased for approximately $0.0610.
How big of a company is Protalex?
Protalex has a market capitalization of $2.89 million. Protalex employs 2 workers across the globe.
What is Protalex's official website?
How can I contact Protalex?
Protalex's mailing address is 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932. The company can be reached via phone at 215-862-9720 or via email at [email protected]
MarketBeat Community Rating for Protalex (OTCMKTS PRTX)
MarketBeat's community ratings are surveys of what our community members think about Protalex and other stocks. Vote "Outperform" if you believe PRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
